A Phase 2 interventional study of GFT505 80mg and Placebo in Insulin Resistance and Abdominal Obesity, sponsored by Genfit. Completed at 2 sites in France. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-09-24.
Sponsored by Genfit · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Insulin Resistance with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Insulin Resistance · France.
Among the 66 studies in Insulin Resistance with a site in France, this one is the 39th largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2011, is one of 4 in phase 2, and was the 21st registered.
2,972 studies on the registry are indexed under Insulin Resistance; 337 are open to participants now.
Browse Insulin Resistance studies →10 of the 66 studies in Insulin Resistance with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Women only
Mondelēz International, Inc. · Sites in France
Ages 18–75 · Healthy volunteers
Fondation Lenval · Sites in France
Ages 2–6
University Hospital, Lille · Sites in France
Ages 18+ · Women only
French Society for Intensive Care · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.
This study: 18 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 7 · Phase 4 5
First in 2002; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.
Median enrollment 40 across the 52 interventional studies, 114 across the 14 observational. Of the 51 that completed or were terminated, 5 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 66 have an industry lead sponsor. The 10 most frequent:
Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Genfit has 1 study filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
4 of the studies in Insulin Resistance with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
| NCT04844684University Hospital, LilleEvaluation of Cortisol and Bile Acids Metabolism in Obese Patients | 2026-12-30 |
| NCT07151924University Hospital, ToulouseEating Disturbances in Patients With Type 1 Diabetes Initiating Insulin Therapy | 2027-02-28 |
| NCT07483723Centre Hospitalier Universitaire, AmiensGlucose Profiles in Women With Polycystic Ovary Syndrome | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Insulin Resistance with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.
The study period per patient is 26 weeks: a selection period will precede a 8-week treatment period, a 6-week wash out period, a second 8-week treatment period in the second arm of treatment and a 2- week follow-up period.
Schedule:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GFT505 80mg
Drug: Placebo
hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Glucose Infusion Rate (GIR)
To evaluate in each patient the differences in Glucose Infusion Rate (GIR) measured at the end of 8 weeks treatment periods with GFT505 (80 mg/day per os) or placebo according to a cross-over design.
Time frame: 8 weeks
Differences in Hepatic Glucose Production (HGP) in each patient
To evaluate in each patient the differences in Hepatic Glucose Production (HGP) measured at the end of 8 weeks treatment periods with GFT505 (80 mg/day per os) or placebo according to a cross-over design.
Time frame: 8 weeks
Changes in GIR (Glucose Infusion Rate)
To compare the changes from baseline to endpoint in Glucose Infusion Rate (GIR). The baseline will be defined as the values of glucose clamp at V2. The same baseline will be used for the 2 periods. End-points will be defined as glucose clamp values at V4 for the first period and as glucose clamp values at V7 for the second period.
Time frame: 8 weeks
Changes in HGP (Hepatic Glucose Production)
To compare the changes from baseline to endpoint in Hepatic Glucose Production (HGP). The baseline will be defined as the values of glucose clamp at V2. The same baseline will be used for the 2 periods. End-points will be defined as glucose clamp values at V4 for the first period and as glucose clamp values at V7 for the second period.
Time frame: 8 weeks
The record gives a start of Jan 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elifibranor